

## **Dimerix Bioscience Board Appointment – Dr Mark Ashton**

MELBOURNE and PERTH, Australia, 6 September, 2011 – The Directors of Dimerix Bioscience Pty Ltd are pleased to advise that Dr Mark Ashton has been appointed a non-executive director of the company.

Dimerix Chairman, Dr David Fuller said: “We are pleased to welcome Dr Ashton to the Board of Dimerix. His appointment brings a high level of expertise to the company given his extensive involvement in the pharmaceutical contract research sector internationally. Together with the company and its other directors Dr Ashton will help support Dimerix’ strategy of developing the next generation drugs targeting GPCR heteromers using its innovative GPCR-HIT technology platform.”

Dr Ashton has over 15 years experience with the European-based Biotech company Evotec, providing integrated drug discovery solutions to the pharmaceutical and biotechnology industry from target to clinic. From 2004-2010, Dr Ashton led the international business development team and activities of Evotec, building up strong networks within the Pharma industry. In October 2010, Dr Ashton moved to Australia to join UniQuest Pty Ltd, one of Australia’s leading research commercialization companies where he is currently Manager of Innovation & Commercial Development.

### **About GPCRs and Dimerix’ GPCR-HIT Platform:**

Dimerix’ proprietary G Protein-Coupled Receptor Heteromer Identification Technology (GPCR-HIT) platform is used to identify complexes formed by GPCRs known as GPCR heteromers. The platform is also used to screen for and to profile compounds that interact with GPCR heteromers resulting in heteromer-selective or biased pharmacology. Use of GPCR-HIT significantly expands the scope of GPCR-based drug discovery and development through the identification of compounds having biased intracellular signaling that is mediated through the GPCR heteromers.

**About Dimerix Bioscience Pty Ltd:**

Dimerix is a private Australian assay technology and drug discovery company focused on developing pharmaceutical products targeting complexes of GPCRs. Additional information about Dimerix is available through its corporate website, [www.dimerix.com](http://www.dimerix.com).

Dimerix is the recipient of a grant from Commercialisation Australia, [www.commercialisationaustralia.gov.au](http://www.commercialisationaustralia.gov.au).

---

**Contact:**

Tim Grogan, Chief Executive Officer (+61 438 655 452)  
or Dr James Williams, Executive Director (+61 409 050 519)

Dimerix Bioscience Pty Ltd

[www.dimerix.com](http://www.dimerix.com)

###